Source:http://linkedlifedata.com/resource/pubmed/id/15685450
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2005-4-19
|
| pubmed:abstractText |
Since advanced prostate cancer is difficult to treat, we have chosen a very different approach: the development of vaccines to prevent initial de novo tumor formation. To test the hypothesis that prostate cancer can be prevented by vaccination, Lobund-Wistar (LW) rats were vaccinated subcutaneously with complete Freund's adjuvant (CFA) plus glutaraldehyde-fixed (GFT) whole cell or potassium thiocyanate extract (PTE) preparations derived from in vivo tumors, or with media and CFA (media-vaccinated). Rats were vaccinated each month substituting incomplete Freund's adjuvant for CFA, from age 3 to 12 months, and methylnitrosourea (30 mg/kg) was administered intravenously at 4 months of age. Groups of 30 GFT cell-vaccinated rats showed a 90% reduction, and PTE-vaccinated rats, a 50% reduction in the occurrence of de novo prostate tumors compared with media-vaccinated controls. When splenocytes from vaccinated rats were incubated with tumor cells prior to subcutaneous implantation, PTE-vaccinated rats showed a 80% reduction, and GFT cell-vaccinated rats showed a 40% reduction in the occurrence of tumors, demonstrating a role for the spleen in the protective response. The inflammatory responses in tumors from GFT cell-vaccinated rats and PTE-vaccinated rats were distinguished by an influx of eosinophils compared with the responses in tumors from media-vaccinated rats. These results demonstrate the possibility that prostate cancer can be prevented by immunization with vaccines based on whole tumor-derived vaccines.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0340-7004
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
54
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
571-6
|
| pubmed:meshHeading |
pubmed-meshheading:15685450-Animals,
pubmed-meshheading:15685450-Cancer Vaccines,
pubmed-meshheading:15685450-Eosinophils,
pubmed-meshheading:15685450-Immunization,
pubmed-meshheading:15685450-Male,
pubmed-meshheading:15685450-Prostatic Neoplasms,
pubmed-meshheading:15685450-Rats,
pubmed-meshheading:15685450-Testosterone
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Prevention of de novo prostate cancer by immunization with tumor-derived vaccines.
|
| pubmed:affiliation |
Lobund Institute, University of Notre Dame, 400 Freimann Life Science Center, Notre Dame, IN, 46556, USA. Suckow.1@nd.edu
|
| pubmed:publicationType |
Journal Article
|